HK1254357A1 - 特異性針對過度磷酸化t蛋白的抗體及其使用方法 - Google Patents

特異性針對過度磷酸化t蛋白的抗體及其使用方法

Info

Publication number
HK1254357A1
HK1254357A1 HK18113433.8A HK18113433A HK1254357A1 HK 1254357 A1 HK1254357 A1 HK 1254357A1 HK 18113433 A HK18113433 A HK 18113433A HK 1254357 A1 HK1254357 A1 HK 1254357A1
Authority
HK
Hong Kong
Prior art keywords
methods
antibodies specific
hyperphosphorylated tau
hyperphosphorylated
tau
Prior art date
Application number
HK18113433.8A
Other languages
English (en)
Inventor
J‧T‧彼得森
L‧Ø‧彼得森
J‧C‧A‧達奇塞爾
A‧阿卜杜勒-拉希德阿蘇尼
N‧羅森奎斯特
Original Assignee
H‧隆德貝克有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1512211.2A external-priority patent/GB201512211D0/en
Priority claimed from GBGB1518375.9A external-priority patent/GB201518375D0/en
Application filed by H‧隆德貝克有限公司 filed Critical H‧隆德貝克有限公司
Publication of HK1254357A1 publication Critical patent/HK1254357A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
HK18113433.8A 2015-07-13 2018-10-19 特異性針對過度磷酸化t蛋白的抗體及其使用方法 HK1254357A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1512211.2A GB201512211D0 (en) 2015-07-13 2015-07-13 Agents, uses and methods
GBGB1518375.9A GB201518375D0 (en) 2015-10-16 2015-10-16 Agents,uses and methods
PCT/EP2016/066470 WO2017009308A2 (en) 2015-07-13 2016-07-12 Antibodies specific for hyperphosphorylated tau and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1254357A1 true HK1254357A1 (zh) 2019-07-19

Family

ID=56557664

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113433.8A HK1254357A1 (zh) 2015-07-13 2018-10-19 特異性針對過度磷酸化t蛋白的抗體及其使用方法

Country Status (32)

Country Link
US (4) US10196439B2 (zh)
EP (1) EP3322442A2 (zh)
JP (1) JP6878395B2 (zh)
KR (1) KR20180030047A (zh)
CN (1) CN107847595B (zh)
AU (1) AU2016292892B2 (zh)
BR (1) BR112018000769A2 (zh)
CA (1) CA2990555A1 (zh)
CL (1) CL2018000096A1 (zh)
CO (1) CO2017013318A2 (zh)
CR (1) CR20180026A (zh)
DO (1) DOP2018000012A (zh)
EA (1) EA038703B1 (zh)
EC (1) ECSP18002644A (zh)
GE (1) GEP20227369B (zh)
HK (1) HK1254357A1 (zh)
IL (1) IL256791B (zh)
JO (1) JO3711B1 (zh)
MA (1) MA42446A (zh)
MX (1) MX2018000505A (zh)
NI (1) NI201800005A (zh)
NZ (1) NZ738595A (zh)
PE (1) PE20180607A1 (zh)
PH (1) PH12018500062A1 (zh)
RU (1) RU2727911C2 (zh)
SG (1) SG10202101343RA (zh)
SV (1) SV2018005611A (zh)
TN (1) TN2017000541A1 (zh)
TW (1) TWI741987B (zh)
UA (1) UA123862C2 (zh)
WO (1) WO2017009308A2 (zh)
ZA (1) ZA201800070B (zh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
RU2732122C2 (ru) 2015-06-05 2020-09-11 Дженентек, Инк. Антитела против тау-белка и способы их применения
EA036821B1 (ru) 2015-07-06 2020-12-23 Юсб Биофарма Срл Тау-связывающие антитела
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
HUE060258T2 (hu) 2016-05-02 2023-02-28 Prothena Biosciences Ltd Tau immunterápia
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JP7029415B2 (ja) 2016-07-12 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
US11590304B2 (en) 2016-08-15 2023-02-28 The Board Of Regents Of The University Of Texas System Volume control device for manually operated resuscitator and ventilation apparatus and method of use
BR112018013247A2 (pt) 2016-10-28 2018-12-04 H Lundbeck As tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos
EP3532053A1 (en) 2016-10-28 2019-09-04 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
CR20190271A (es) 2016-12-07 2019-09-03 Genentech Inc Anticuerpos antitau y métodos de uso
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
EP3565836A1 (en) * 2017-01-04 2019-11-13 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
EA039569B1 (ru) * 2017-03-14 2022-02-11 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
CU24636B1 (es) 2017-05-02 2022-12-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
MA50397A (fr) 2017-10-16 2020-08-26 Eisai R&D Man Co Ltd Anticorps anti-tau et leurs utilisations
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
PL3723807T3 (pl) 2017-12-14 2022-01-24 H. Lundbeck A/S Leczenie skojarzone obejmujące podawanie 1h-pirazolo­[4,3-b]pirydyn
WO2019121840A1 (en) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
US11274147B2 (en) 2018-02-01 2022-03-15 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
JP2022524588A (ja) 2019-03-03 2022-05-09 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
JP2022527087A (ja) 2019-03-28 2022-05-30 ハー・ルンドベック・アクチエゼルスカベット タウオパチーを診断するためのｐＳ３９６アッセイの使用
BR112022020753A2 (pt) 2020-04-15 2022-12-20 Voyager Therapeutics Inc Compostos de ligação a tau
US20230265175A1 (en) 2020-06-25 2023-08-24 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
CA3194752A1 (en) * 2020-09-11 2022-03-17 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
AU2021339754A1 (en) 2020-09-11 2023-05-25 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
WO2022104136A2 (en) * 2020-11-12 2022-05-19 Children's Medical Center Corporation Methods and compositions for tauopathy diagnosis and treatment
MX2023007181A (es) 2020-12-16 2023-08-30 Voyager Therapeutics Inc Compuestos de union a tau.
CN113702647B (zh) * 2021-08-31 2024-03-15 普十生物科技(北京)有限公司 人生长分化因子15即时检测试剂盒、其制备方法及其应用
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023250388A1 (en) 2022-06-22 2023-12-28 Voyager Therapeutics, Inc. Tau binding compounds
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
WO2024067401A1 (zh) * 2022-09-26 2024-04-04 中美华世通生物医药科技(武汉)股份有限公司 包含Fc-高级脂肪酸链的超长效平台

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5102990A (en) 1989-08-09 1992-04-07 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
EP2009104A1 (en) 1991-12-06 2008-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
ES2228467T3 (es) 1999-02-03 2005-04-16 Biosante Pharmaceuticals, Inc. Particulas terapeuticas de fosfato calcico y metodos de fabricacion y su uso.
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
EP1210372B1 (en) 1999-07-29 2008-01-23 Medarex, Inc. Human monoclonal antibodies to her2/neu
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
TWI313299B (en) 2000-11-30 2009-08-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20070134724A1 (en) 2005-08-04 2007-06-14 Peter Davies Phosphorylation of tau by abl
JP5525729B2 (ja) 2005-11-28 2014-06-18 ゲンマブ エー／エス 組換え一価抗体およびその作製方法
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
WO2009033743A1 (en) 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2765099A1 (en) 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
SG10201406839VA (en) 2009-10-26 2014-12-30 Otsuka Pharma Co Ltd Benzazepine compound
US9304138B2 (en) * 2010-10-07 2016-04-05 Katholieke Universiteit Leuven Pharmaceutical composition
ES2686550T3 (es) 2010-10-11 2018-10-18 Biogen International Neuroscience Gmbh Anticuerpos anti-tau humanos
AU2012311234B2 (en) * 2011-09-19 2017-09-28 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease
EP3135689B1 (en) * 2011-10-07 2018-12-19 AC Immune S.A. Phosphospecific antibodies recognising tau
BR112014024769A2 (pt) 2012-04-05 2017-12-12 Ac Immune Sa anticorpo humanizado tau
US9834596B2 (en) 2012-07-03 2017-12-05 Washington University Antibodies to tau
GB2507207A (en) 2012-08-16 2014-04-23 Ipierian Inc Treatment of Tauopathies
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US20160068818A1 (en) * 2013-04-16 2016-03-10 Glykos Finland Oy A method for generating induced pluripotent stem cells
WO2016007414A1 (en) 2014-07-08 2016-01-14 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JP7029415B2 (ja) 2016-07-12 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3565836A1 (en) 2017-01-04 2019-11-13 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
US10934438B2 (en) 2017-04-27 2021-03-02 Axalta Coating Systems Ip Co., Llc Coatings and methods for using and producing the same

Also Published As

Publication number Publication date
RU2727911C2 (ru) 2020-07-24
US20190177401A1 (en) 2019-06-13
IL256791B (en) 2022-09-01
US10562962B2 (en) 2020-02-18
JP6878395B2 (ja) 2021-05-26
US20200190178A1 (en) 2020-06-18
US10934348B2 (en) 2021-03-02
UA123862C2 (uk) 2021-06-16
CO2017013318A2 (es) 2018-05-21
CA2990555A1 (en) 2017-01-19
MA42446A (fr) 2018-05-23
EP3322442A2 (en) 2018-05-23
IL256791A (en) 2018-03-29
SV2018005611A (es) 2018-02-23
MX2018000505A (es) 2018-04-30
CN107847595A (zh) 2018-03-27
RU2018100822A (ru) 2019-08-13
BR112018000769A2 (pt) 2018-09-25
NZ738595A (en) 2022-07-01
PH12018500062A1 (en) 2018-07-09
AU2016292892B2 (en) 2021-11-18
US20170015738A1 (en) 2017-01-19
US11739140B2 (en) 2023-08-29
GEP20227369B (en) 2022-04-11
PE20180607A1 (es) 2018-04-09
NI201800005A (es) 2018-10-19
EA038703B1 (ru) 2021-10-07
JP2018531580A (ja) 2018-11-01
WO2017009308A2 (en) 2017-01-19
CL2018000096A1 (es) 2018-07-06
CR20180026A (es) 2018-03-08
TN2017000541A1 (en) 2019-04-12
RU2018100822A3 (zh) 2019-12-26
DOP2018000012A (es) 2018-02-28
SG10202101343RA (en) 2021-03-30
CN107847595B (zh) 2021-09-24
JO3711B1 (ar) 2021-01-31
ZA201800070B (en) 2019-04-24
AU2016292892A1 (en) 2018-01-18
TWI741987B (zh) 2021-10-11
WO2017009308A3 (en) 2017-04-06
ECSP18002644A (es) 2018-03-31
US10196439B2 (en) 2019-02-05
TW201716436A (zh) 2017-05-16
KR20180030047A (ko) 2018-03-21
US20210206843A1 (en) 2021-07-08
EA201890039A1 (ru) 2018-08-31

Similar Documents

Publication Publication Date Title
HK1254357A1 (zh) 特異性針對過度磷酸化t蛋白的抗體及其使用方法
ZA201808329B (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
HK1258058A1 (zh) 抗tigit抗體和使用方法
HK1249445A1 (zh) 抗分揀蛋白抗體和其使用方法
IL259495A (en) Antibodies and methods for using them
HK1252698A1 (zh) 抗siglec-9抗體及其使用方法
HK1252858A1 (zh) 抗cll-1抗體和使用方法
HK1247569A1 (zh) 抗pvrig抗體和使用方法
HK1252696A1 (zh) 抗siglec-7抗體及其使用方法
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
HK1254743A1 (zh) 新穎抗密封蛋白抗體及使用方法
ZA202001985B (en) Anti-htra1 antibodies and methods of use thereof